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Abstract
Background
The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with
multiple sclerosis (MS). However, this drug is associated with increased risk of developing
Progressive Multifocal Leukoencephalopathy (PML), an opportunistic infection of central
nervous system (CNS) caused by the John Cunningham polyomavirus (JCV).
Objective
To describe the 12-month clinical course of 39 patients with MS (28 women, 11 men) who
developed NTZ-related PML after a mean exposure of 39 infusions.
Methods
An Italian independent collaborative repository initiative collected and analyzed socio-demo-
graphic, clinical, magnetic resonance imaging (MRI) data and number of JCV-DNA copies
detected on cerebrospinal fluid (CSF) samples of patients diagnosed as affected by NTZ-
related PML. The evolution of disability, measured by the Expanded Disability Status Scale,
was assessed at NTZ start, at PML diagnosis and after 2, 6 and 12 months from PML diag-
nosis. The effect of clinical and paraclinical characteristics at PML diagnosis on the final out-
come was also investigated.
Results
Ten patients (25.6%) were diagnosed before 24 NTZ infusions. In six cases (15.4%) the
PML suspect was made on the basis of highly suggestive MRI findings in absence of any
detectable change of clinical conditions (asymptomatic PML). In patients with symptomatic
PML, the diagnosis was quicker for those who presented with cognitive symptoms (n = 12)
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rather than for those with other neurological pictures (n = 21) (p = 0.003). Three patients
(7.7%) died during the 12-month observation period, resulting in a survival rate of 92.3%.
Asymptomatic PML, more localized brain involvement and gadolinium-enhancement
detected at MRI, as well as lower viral load were associated with a better disability outcome
(p-values<0.01).
Conclusion
Our findings support that early PML diagnosis, limited CNS involvement and initial signs of
immune restoration are associated with a better outcome and higher survival rate, and con-
firm the utility of MRI as a surveillance tool for NTZ-treated patients.
Introduction
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection that usually
occurs in immunocompromised patients [1]. The causative agent of PML is the John Cunning-
ham virus (JCV), a polyomavirus which mainly infects oligodendrocytes and astrocytes, even
if some variants may involve neurons (cortical pyramidal and cerebellar granule cells) [2,3].
In addition to being widely studied in patients with human immunodeficiency virus (HIV)
over the last decade [4], PML has also been observed in patients with multiple sclerosis (MS)
treated with natalizumab (NTZ) [5–7], a monoclonal antibody which suppresses immune sur-
veillance in the central nervous system (CNS) by preventing the immune system to enter the
CNS [8,9]. The estimated incidence of NTZ-related PML is in the order of 4.15 per 1000
patients, with a mortality rate of about 24%, according to manufacturer report [10]. Patients
treated with NTZ are considered at higher risk for developing PML if they have tested positive
for JCV, and have received more than 24 infusions, and either if they have previoulsy used an
immunosuppressant, or have not used immunosuppressants and have a high JCV antibody
index [11,12].
The course and outcome of PML is influenced not only by the lytic action of JCV, but also
by the impact of the immune reconstitution inflammatory syndrome (PML-IRIS), i.e. the
excessive inflammatory reaction occurring as a result of the reconstitution of the immune sys-
tem in a previously immunocompromised patient [13]. In the event of PML-IRIS, the over-
whelming immune response is directly responsible for the worsening of the patient’s clinical
condition [14] and the magnetic resonance imaging (MRI) findings of extension of the lesion
(s) coupled with enhancement and oedema [15].
Some clinical and paraclinical features at NTZ-related PML diagnosis have been reported
to be predictive of bad outcome, including older age, high pre-PML disability, MRI findings
consistent with multifocal damage, elevated number of JCV copies detected in cerebrospinal
fluid (CSF) and symptomatic PML [16–18]. However, literature data regarding clinical out-
comes after PML suffer from several biases, including incomplete data collection, largely het-
erogeneous management of patients and not univocal definition of PML-IRIS [15, 19]. This
latter point is of particular relevance, since a correct interpretation of MRI is crucial to deter-
mine appropriate therapeutic strategy. Inflammation detected at MRI does not necessarily
imply the occurrence of PML-IRIS. A productive brain reaction against JCV can be also
detected as perivascular inflammation and enhancement (inflammatory PML). In this latter
case, misdiagnosis as PML-IRIS and consequent treatment with early corticosteroids may lead
to the worsening of patient’s clinical outcome [20].
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Therefore, in the current paper we would carefully illustrate the clinical characteristics of 40
Italian patients with MS who developed NTZ-induced PML and their longitudinal clinical evo-
lution up to 12 months after the PML diagnosis. In addition, we sought to identify if there was
any socio-demographic, clinical, or MRI feature at PML diagnosis that influenced the longer-
term outcome.
Materials and Methods
Patients ascertainment
An Italian independent spontaneous collaborative repository initiative made a registry for the
collection of complications in patients with MS treated with NTZ. Thirty two Italian sites took
part to the initiative. Data of patients who received a definite, probable or possible diagnosis of
NTZ-related PML according to AAN criteria [21] were retrospectively collected and stored by
the MS centre of Montichiari (Brescia), the reference site for NTZ-related PML cases in Italy.
Each site regularly followed-up the patients from the start of NTZ treatment according to
standard clinical practice and recommendation provided by the Italian regulatory agency
(Agenzia Italiana del Farmaco, AIFA) [22]. Clinical data including Expanded Disability Status
Scale (EDSS) [23] scoring and relapse recording were then prospectively collected with at least
quarterly evaluations from NTZ start [24]. Patients were scanned for brain MRI with 1.5T or
3.0T magnets at NTZ start and at least yearly during NTZ treatment, according to standard-
ized procedures [25]. Since the introduction of STRATIFY test to detect serum anti-JCV anti-
bodies in 2011 [26], patients with a negative anti-JCV antibody test were re-tested periodically
(at least yearly), and those who were at high risk of developing PML were scanned every 3 or 4
months throughout NTZ treatment [5].
CSF samples were collected at PML suspicion and sent to the National Institute of Health
(NIH) Laboratory of Molecular Medicine and Neuroscience (Bethesda, MD, USA) in 35 cases;
4 specimens were analyzed in local labs; the remaining specimen was analyzed in FOCUS lab
(Cypress, CA, USA). JCV-DNA copies were searched on CSF samples by quantitative poly-
merase chain reaction (PCR).
The retrospective analysis of patients’ data was approved by the ethical committee of the
Spedali Civili of Brescia and was conducted in accordance with specific national laws and the
ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. In
no way did this study interfere in the Care received by patients.
Data collection
Socio-demographic, clinical and MRI data were extracted by patient charts and stored into a
centralized database.
Socio-demographic data included: sex; age at NTZ start; age at PML diagnosis.
Clinical data included: previous immune suppression; total number of NTZ infusions;
annual relapse rate (ARR) in the year before NTZ start and during NTZ treatment; symptom-
atic or asymptomatic PML (i.e. detection of PML lesions at brain MRI scan in absence of new
signs or symptoms); number of JCV-DNA copies detected with PCR performed on CSF sam-
ples at PML suspect; longitudinal EDSS scores collected at NTZ start (hereafter referred as
baseline), at PML diagnosis (M0), at two months (M2), six months (M6) and 12 months
(M12) from PML diagnosis (see Fig 1 for the main time frames considered in our patients).
MRI data included: presence or absence of contrast-enhancement in PML lesion(s); pres-
ence or absence of the radiological features of PML-IRIS (see below); lesion patterns classified
as unilobar (confined to one lobe), multilobar (involving two or more contiguous lobes), wide-
spread (involving two or more non-contiguous lobes and/or present in both hemispheres)
Italian Natalizumab-Related PML Registry
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[27] and infratentorial. We considered infratentorial PML lesions separately from the other
patterns for two main reasons: (i) infratentorial lesions are known to have high predictive
value for long-term disability even in MS pathology [28–30]; (ii) infratentorial lesions, particu-
larly if involving the brainstem, need to be considered with particular attention due to the
potentially life-threatening complications of oedema and mass effect in these situations [6].
MRI data harmonization
Brain images were reviewed centrally by the sites of Brescia (Montichiari) and Milano (San
Raffaele). Two neurologists (RC, NDR) and two neuroradiologists (MC, SG) reviewed the data
independently. Clinical and MRI data were subsequently discussed in parallel to avoid poten-
tial bias due to conflicting definition of PML-IRIS [10,20,31–33].
We defined PML-IRIS as the presence of specific radiological changes of PML lesion associ-
ated with an almost concomitant unexpected abrupt and severe worsening of clinical condi-
tions [13–15,34]. Radiological features of PML-IRIS consisted in an important inflammatory
reaction with swelling or oedema of PML lesion(s) and possible mass effect [29–34]. A “ring-
like” or “wave-like” alteration of the blood-brain barrier (BBB) at the periphery of the PML
lesion(s) may be also detected [29–34]. We differentiated PML-IRIS from the so-called
“inflammatory PML”, whose MRI features are characterized by oedema without significant
mass effect, somewhat associated with punctuate BBB disruption not only in PML lesion(s),
but also in other parts of the brain [35]. This MRI pattern is associated with slow and steady
worsening of clinical status [35], which is thought to be temporally related with recovery of the
immune system and inflammatory response to JCV [36].
Statistical analyses
Categorical variables are expressed as count (percentage) and continuous variables as mean
(SD) or median (range), as appropriated. Between-group differences were tested using the
Chi-squared or the U Mann-Whitney tests for categorical and continuous variables, respec-
tively. The longitudinal clinical course of patients was explored by repeated measures analysis
of the variance (RM-ANOVA) after testing the assumptions of sphericity and normality at
each assessment, and with the Student-Newman-Keuls (S-N-K) as post-hoc test. The EDSS
score was defined as dependent variable and time (5 levels: baseline, M0, M2, M6 and M12) as
the within-subject factor. Potential predictors of clinical course were investigated either by
inserting categorical variables of interest as between-group factor or by performing Spearman
Rank Correlation coefficients between continuous variables of interest and EDSS changes,
Fig 1. Assessments of patients who developed natalizumab-related progressive multifocal leukoencephalopathy.
doi:10.1371/journal.pone.0168376.g001
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calculated by subtracting the EDSS score at baseline from the EDSS score at each of the follow-
ing assessments (M0, M2, M6, M12) for each patient.
Due to the exploratory nature of this study, no correction for multiple comparisons was
applied.
All data were analyzed by using the Statistical Package for Social Science version 16.0 (IMB
SPSS, Chicago, Ill, USA).
Results
Patient demographic and clinical features
From January 2009 to April 2016, 44 patients with MS received a diagnosis of NTZ-related
PML in Italy, and 39 among them were inserted into the database (S1 Table). Their main
socio-demographic and clinical characteristics are reported in Table 1.
Five patients were not included in the database for the following reasons: data unavailability
for three patients, including too short observation period; one patient refused to provide
informed consent; in one patient the PML diagnosis cannot be confirmed and then he was
classified as “possible” PML.
This latter 33-year-old male patient, who did not receive previous immunosuppressant
drugs, developed difficulty in sustained attention followed by impaired dexterity on the right
hand after 47 infusions. Brain MRI scan revealed a non-enhancing parietal lesion highly sug-
gestive of PML, but the JCV-DNA searching was negative in 5 consecutive CSF samples. The
patient refused brain biopsy.
All the patients who were tested were positive for anti-JCV antibodies. Five patients diag-
nosed before the introduction of STRATIFY test were not tested. No patient was tested anti-
JCV negative.
Out of 39 patients, 13 (33.3%) were previously treated with one or more immunosuppres-
sant agents before NTZ beginning. In particular, they were treated with mitoxantrone only
(n = 6), azathioprine and mitoxantrone (n = 3); azathioprine only (n = 1), azathioprine and
methotrexate (n = 1); cyclophosphamide and mitoxantrone (n = 1); and azathioprine, cyclo-
phosphamide and mitoxantrone (n = 1).
The median ARR decreased from 2 (range 1–4) in the year before NTZ start to 0 (range
0–1) during NTZ treatment (p<0.001).
PML diagnosis
Patients received a mean (SD) number of 38.6 (18.2) NTZ infusions (range 11 to 86) before
PML diagnosis. In one patient (2.6%), the PML diagnosis was made within the first year of
NTZ treatment (after 11 infusions), in 9 patients (23.1%) between the 12th and 24th NTZ infu-
sion; in 9 patients (23.1%) between the 25th and 36th NTZ infusion; in 8 patients (20.5%)
between the 37th and 48th NTZ infusion; in 7 patients (17.9%) between the 49th and 54th
NTZ infusion; in 5 patients (12.8%) after the 64th NTZ infusion.
Patients who were diagnosed before receiving 24 NTZ infusions (n = 10) were older at NTZ
start than those who were diagnosed thereafter (n = 29) (43.5±9.7 vs. 36.9±8.3 years, p = 0.03);
there was no other difference in demographic, clinical, MRI and paraclinical features (includ-
ing JCV-DNA copies on CSF).
There was no difference in mean number of NTZ infusions received before PML diagnosis
between patients previously treated with immunosuppressant drugs (n = 13) and those who
did not (n = 26) (35.8±13.4 vs. 40.4±20.3 infusions, respectively; p = 0.71).
The PML suspect was made on the basis of deteriorating neurological conditions in 33
(84.6%) cases (symptomatic PML), including cognitive symptoms (n = 13), motor symptoms
Italian Natalizumab-Related PML Registry
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Table 1. Socio-demographic and clinical features of each individual patient (n = 40).
Patients Age at PML
onset (years)
Gender Disease
Duration (years)
ARR pre-
natalizumab
ARR during
natalizumab
EDSS at NTZ
beginning
EDSS at PML
onset
Number of
infusions
Overall* 41.8 ± 8.5 11 M; 28 F 13.6 ± 7.2 2 (0–4) 0 (0–1) 3.9 ± 1.9 4.8 ± 2.1 38.6 ± 18.2
95% CIs 39.1 to 44.6 7 to 18 M; 22
to 33 F
11.3 to 15.9 1.54 to 2.05 0.03 to 0.23 3.3 to 4.5 4.1 to 5.5 32.7 to 44.5
1 47 F 18 2 0 5.5 6.5 17
2 52 M 12 3 0 2.0 6.0 11
3 38 F 12 2 0 2.0 3.0 21
4 30 F 7 1 0 6.5 8.0 50
5 43 F 2 1 0 3.5 3.5 45
6 46 M 11 2 0 2.0 2.0 30
7 32 F 3 3 0 2.0 4.0 20
8 43 F N/A 1 0 6.5 7.0 34
9 54 F 22 2 0.05 5.0 6.0 42
10 23 F 11 1 0 2.5 2.0 44
11 51 F N/A 3 0 6.5 6.5 21
12 46 F 16 2 0 5.5 4.5 39
13 46 M 20 1 0 6.0 7.0 17
14 46 M 8 1 0 3.0 3.5 29
15 51 M 22 1 1 3.5 5.0 34
16 28 F 4 3 1 1.0 3.5 25
17 41 F 20 2 1 6.5 8.5 31
18 60 F 36 2 0 6.0 7.5 13
19 47 F 19 1 0 5.5 7.5 21
20 48 F 14 2 0 3.5 3.5 16
21 56 F 14 2 0 4.0 4.0 48
22 22 F 5 3 0 2.0 2.5 51
23 47 F 24 2 0 7.0 6.5 37
24 43 M 25 1 0 6.5 6.5 63
25 38 M 11 2 0 1.5 2.5 27
26 39 F 10 2 0 2.0 2.0 45
27 45 F 9 1 0 1.5 3.0 45
28 37 M 7 1 0 4.0 6.5 52
29 29 M 6 1 0 2.5 3.0 24
30 38 F 16 1 0.5 4.5 8.0 37
31 36 F 17 2 0.17 3.5 5.5 78
32 46 F 11 4 0 2.0 2.0 64
33 34 F 6 2 1 4.0 5.0 58
34 38 M 18 1 0 3.0 7.5 67
35 42 F 10 1 0 2.5 3.5 28
36 49 M 11 2 0 3.5 3.5 86
37 44 F 21 2 0.3 6.5 7.5 27
38 38 F 17 N/A 0.01 0.0 0.0 55
39 38 F 9 2 0 6.0 3.5 55
* Values are mean ± standard deviation, or median (range) or number.
95% CIs: 95% confidence intervals; F: female; M: male; ARR, annual relapse rate; EDSS, Expanded Disability Status Scale; PML, progressive multifocal
leukoencephalopathy; N/A: not available.
doi:10.1371/journal.pone.0168376.t001
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(n = 7); signs and/or symptoms indicative of brainstem/cerebellar involvement (n = 3); cogni-
tive and motor symptoms (n = 3); motor and brainstem/cerebellar involvement (n = 2); visual
deficit (n = 2); epilepsy (n = 1); epilepsy and cognitive symptoms (n = 1); and verbal hallucina-
tions (n = 1). In the remaining 6 (15.4%) cases, there were MRI findings highly suggestive of
PML in absence of any detectable change of clinical conditions (asymptomatic PML). These
six asymptomatic patients performed MRI every six months (n = 2), every four months (n = 2)
or every three months (n = 2).
Interestingly, the diagnosis was quicker for patients who presented only with cognitive
symptoms (n = 13) rather than for those with other neurological pictures (n = 20), being the
mean days from symptom onset to PML diagnosis of 23.2±11.4 vs. 45.7±18.8 days, respectively
(p = 0.006).
MRI patterns and CSF findings
Out of 39 patients, 13 (33.3%) presented with an unilobar lesion, 13 (33.3%) with multilobar
lesions, 6 (15.4%) with widespread lesions and 7 (17.9%) with an infratentorial lesion. Con-
trast-enhancement of PML lesion(s) was found in 14 (35.9%) patients, without any significant
relationship with MRI patterns (p = 0.78). In particular, contrast-enhancement occurred in 4
patients who presented with unilobar lesion, in 5 with multilobar lesion, in 2 with widespread
lesion and in 3 with infratentorial lesion.
The median number of viral copies/ml detected in CSF at PML diagnosis was 230.5 (range
10–26,300).
Relationships between clinical, MRI features and laboratory findings at PML diagnosis are
presented in Table 2. Patients who presented with an unilobar lesion (n = 13) had lower num-
ber of viral copies/ml in the CSF compared with patients with other MRI patterns (n = 26),
with a statistical trend toward significance (p = 0.09). Interestingly, patients who presented
with contrast-enhancement had a lower number of viral copies/ml in the CSF compared with
patients without contrast-enhancement (p = 0.03).
Table 2. Relationships between MRI features and clinical and laboratory findings at PML onset.
MRI patterns Contrast-enhancement
Unilobar
(n = 13)
Multilobar
(n = 13)
Widespread
(n = 6)
Infratentorial
(n = 7)
Yes (n = 14) No (n = 25)
Asymptomatic onset (n = 6) 4 0 0 2 1 5
Symptomatic onset (n = 33) 9 13 6 5 13 20
Cognitive symptoms only (n = 13) 2 6 5 0 3 10
Motor symptoms only (n = 7) 4 2 0 1 4 3
Brainstem or cerebellar symptoms only
(n = 3)
2 0 0 1 1 2
Cognitive AND motor symptoms (n = 3) 0 2 0 1 2 1
Motor AND brainstem or cerebellar
symptoms (n = 2)
0 0 1 1 1 1
Epilepsy (n = 1) 0 0 0 1 1 0
Epilepsy AND cognitive symptoms (n = 1) 1 0 0 0 0 1
Visual loss (n = 2) 0 2 0 0 0 2
Verbal hallucination (n = 1) 0 1 0 0 1 0
JCV-DNA copies/ml on CSF,median
(range)
63 (10–26,300) 542 (12–3,932) 327.5 (31–5,174) 294 (15–4,403) 67.5 (21–
2,322)
366 (10–
26,300)
doi:10.1371/journal.pone.0168376.t002
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Clinical outcome
The mean EDSS score worsened from baseline (i.e. NTZ start) to M0 (i.e. PML diagnosis) (3.9
±1.9 vs. 4.8±2.1; p<0.001). The assumption of normal distribution of EDSS scores was satisfied
at all assessments (p>0.2 by the Kolmogorov-Smirnov test), therefore we analyzed the mean
scores throughout the 12-month observational period. The main effect of time on EDSS scores
was significant (F4,148 = 28.2, p<0.001). The S-N-K post-hoc test revealed that the EDSS score
was significantly lower at baseline and M0 than at following assessments (all p-values<0.001).
The analysis of EDSS changes from baseline to different following assessments showed that the
peak of disability worsening occurred at 6 months from PML diagnosis (Fig 2). At the end of
the 12-month observation, 15 (38.4%) patients accumulated up to 1-EDSS point, 9 (23.1%)
patients 2-EDSS points, 15 (38.4%) patients 3-EDSS points or more with respect to baseline.
Three out of 39 patients died during the first year after PML diagnosis, resulting in a sur-
vival rate of 92.3%; two patients died during PML-IRIS, while one patient died after 6 months
from PML diagnosis due to complication of an acute acalculous cholecystitis.
PML-IRIS
Out of 39 patients, 27 (69.2%) had a PML-IRIS after 82.5±29.2 days following NTZ withdrawal.
There was no difference between patients who developed PML-IRIS and those who did not in
demographic and clinical characteristics (all p-values>0.15). Out of 12 patients who did not
developed PML-IRIS, 9 were treated with plasma exchange (PLEX), and all of them were
treated with steroids when their clinical profile was worsening. Nine patients were also treated
with an additional therapy (maraviroc, mefloquine or mirtazapine). However, PML-IRIS
insurgence was not related to the administration of these therapies, including PLEX, steroids,
and other therapies (all p-values>0.12).
Among patients previously treated with immunosuppressant agents (n = 13), 9 developed
PML-IRIS and 4 did not (p = 0.87), therefore ruling out the possibility that prior immune sup-
pression might have dampen the PML-IRIS occurrence.
The PML-IRIS emergence was related neither with the number of JCV-DNA copies
(median: 172 and 200.5 in patients with or without PML-IRIS, respectively; p = 0.97) nor with
the MRI patterns (p-values>0.4). In more details, PML-IRIS occurred in patients who pre-
sented with unilobar lesion in 9 cases, multilobar lesions in 9 cases, widespread lesions in 4
Fig 2. Longitudinal evolution of disability throughout the 12-month observational period.
doi:10.1371/journal.pone.0168376.g002
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cases and brainstem lesion(s) in 5 cases. Accordingly, patients without PML-IRIS presented
with unilobar lesion in 4 cases, multilobar lesions in 4 cases, widespread lesions in 2 cases and
brainstem lesion(s) in 2 cases.
Predictors of clinical outcome
We investigate whether the 12-month longitudinal clinical course of patients could have been
affected by some factors at PML diagnosis, such as NTZ treatment duration (less or more than
24 infusions), asymptomatic PML, presence of contrast-enhancement at PML suspect, MRI
patterns and number of JCV-CSF copies. However, due to the small sample size of subgroups,
the results outlined in this paragraph should be should be interpreted with caution and consid-
ered only as preliminary.
NTZ treatment duration. We found no time by group interaction effect (F4,148 = 1.10,
p = 0.35) in patients who developed PML before (n = 10) or after (n = 29) receiving 24 NTZ
infusions.
Asymptomatic PML. The S-N-K post-hoc test revealed a different longitudinal course in
patients with asymptomatic PML (n = 6) and in those with symptomatic PML (n = 33) (Fig
3A). The mean EDSS score of asymptomatic cases did not change from baseline to M0 (3.4
±1.2 vs. 4.0±1.6, p = 0.18). However, the mean EDSS score worsened from baseline to M2 (4.7
±2.3, p = 0.02), M6 (5.1±2.5, p = 0.007) and M12 (4.7±2.1, p = 0.01). We found no difference
from M0 to the subsequent assessments and across M2, M6 and M12 assessments. On average,
Fig 3. Disability changes throughout the 12-month observational period according to clinical and
paraclinical characteristics (A: symptomatic versus asymptomatic presentation; B: absence versus
presence of contrast-enhancement at PML diagnosis; C: unilobar versus other MRI patterns; D: correlation
with CSF-JCV viral load).
doi:10.1371/journal.pone.0168376.g003
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patients with asymptomatic PML accumulated 1.3±1.4 EDSS points from baseline to M12 and
0.7±1.2 points from M0 to M12. In patients with symptomatic PML, the mean EDSS score sig-
nificantly worsened from baseline to M0 (4.1±1.7 vs. 5.1±2.0, p = 0.002), M2 (6.1±2.1,
p<0.001), M6 (6.9±2.0, p<0.001) and M12 (6.4±2.3, p<0.001). Moreover, the EDSS score
worsened even from M0 to M2, M6, and M12 (p-values<0.01), while there were no differences
across the post-PML onset assessments. On average, patients with symptomatic PML accumu-
lated 2.4±2.1 EDSS points from baseline to M12 and 1.3±1.9 points from M0 to M12. All dead
patients had a symptomatic PML onset.
Contrast-enhancement. We found a significant time by group interaction effect
(F4,148 = 4.87, p<0.001), indicating a different longitudinal course in patients with (n = 14)
and without (n = 25) contrast-enhancement (Fig 3B). The mean EDSS score of patients with
contrast-enhancement significantly worsened from baseline (4.6±2.1) to the next assessments
(p-values<0.05). There were no differences in EDSS scores from M0 (5.6±2.1) to M2 (5.5
±2.2), M6 (6.2±1.6), and M12 (5.8±2.0) (p-values>0.5). Furthermore, there was no difference
across different post-PML onset assessments. On average, patients with contrast-enhancement
accumulated 1.2±1.3 EDSS points from baseline to M12, and 0.2±1.1 points from M0 to M12.
The mean EDSS score of patients without contrast-enhancement significantly worsened from
baseline (3.4±1.6) to the following assessments (p-values<0.02). We found significant differ-
ences in mean EDSS scores from T0 (4.3±2.0) to M2 (5.8±2.5), M6 (6.7±2.6) and M12 (6.2
±2.7) (p-values<0.01). There was no differences across different post-PML onset assessments.
On average, patients without contrast-enhancement accumulated 2.8±1.2 EDSS points from
baseline to M12 and 1.6±1.1 points from M0 to M12. Dead patients showed no contrast-
enhancement at the PML suspect.
MRI patterns. We found a time by group interaction effect (F4,148 = 2.82, p = 0.02), indi-
cating a different longitudinal course in patients with unilobar lesion (n = 13) and in those who
presented other MRI patterns (n = 26) (Fig 3C). The mean EDSS score of patients with unilobar
lesion did not change from baseline to M0 (3.5±1.7 vs. 4.1±1.6; p = 0.25), while there was a slight
worsening at M2 (4.4±1.9; p = 0.09) and an overt worsening at M6 (5.1±2.3, p<0.01) and M12
(4.7±2.3, p<0.01). We found no differences in EDSS scores from M0 to the next assessments
(p-values>0.1). On average, patients with an unilobar lesion accumulated 1.2±1.6 EDSS points
from baseline to M12 and 0.6±1.7 points from M0 to M12. On the contrary, the EDSS score of
patients with MRI patterns other than unilobar lesion worsened from baseline to M0 (4.0±2.0
to 5.1±2.3; p = 0.07) M2 (6.4±2.3), M6 (7.2±1.9) and M12 (6.7±2.2) (p-values<0.001). Signifi-
cant differences emerged also in EDSS scores between M0 and the following assessment (p-
values<0.001). On average, patients with MRI patterns other than unilobar PML lesion accu-
mulated 2.7±2.4 EDSS points from baseline to M12 and 1.6±1.9 points from M0 to M12.
Dead patients had the following MRI patterns: (i) infratentorial lesion; (ii) unilobar lesion
located in the left temporal lobe; (iii) widespread pattern involving the fronto-temporo-parietal
white matter of the left hemisphere.
Viral load. We found the number of viral copies to be strongly correlated with EDSS
changes: M2-M0 (r = 0.47; p = 0.002), M6-M0 (r = 0.49; p = 0.001), and M12-M0 (r = 0.53;
p<0.001) (Fig 3D). The highest values of viral copies (>4,403) were detected in the 3 patients
who died within the first year after PML diagnosis.
Discussion
The current paper analyzes the longitudinal data of 39 Italian patients who developed NTZ-
related PML between 2009 and 2016. Our analysis largely confirms literature data and offers
some new insights about this topic.
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Consistently with previous observations, NTZ-related PML evolves in a timeframe from 6
to 12 months, with the peak of disability at 6 months and a variable degree of recovery at 12
months from the diagnosis [14,17,18,37,38]. Accordingly, we observed all deaths around 6
months from PML diagnosis [14,18]. Our study corroborates previous findings that asymp-
tomatic PML, more localized brain involvement and lower JCV viral load at PML diagnosis
are associated with better outcomes. The three deaths occurred indeed in patients with symp-
tomatic PML and higher numbers of CSF-DNA viral copies at PML diagnosis. This is in line
with previously published data on predictors of survival and functional outcomes [16–18] and
indicates that the later the PML diagnosis was made, the more the disease was widespread.
Therefore, our study strongly supports the deferral of further NTZ dosing until exclusion of
PML diagnosis in case of unexpected clinical worsening or new MRI lesions occurring beyond
the first year of therapy [39].
The current paper also highlights some new features with respect to existing literature,
including: (i) a higher survival rate; (ii) a higher percentage of asymptomatic patients at PML
suspect; (iii) a shorter time to diagnosis in patients with a cognitive PML onset; (iv) a relevant
proportion (25.6%) of patients who developed NTZ-related PML before the 24th infusion; (v)
a different clinical course between patients with and without MRI enhancement of PML
lesion(s); (vi) a lower prevalence of PML-IRIS onset.
The 92.3% survival rate after one year from PML diagnosis found in the Italian cohort is
higher than most of previously published studies (70–80%) [1,18,37]. This latter finding proba-
bly reflects the higher proportion (15.4%) of asymptomatic PML in our cohort compared with
other datasets (see for example the paper by Dong-Si and coll. [17] reporting an 8% of asymp-
tomatic PML). As reported by previous studies, asymptomatic PML cases showed a single
localized lesion at brain MRI, with unilobar or infratentorial patterns [39]. The presence of
more localized lesions in asymptomatic patients probably mirrors the stringent application of
national recommendation regarding more frequent MRI scans in patients at high risk of devel-
oping PML [24]. In our cohort, asymptomatic PML cases underwent brain MRI scans two,
three of four times per year, supporting the advice that more frequent MRI examinations are
helpful for an early identification of PML. This is also in line with the recently published inter-
national MAGNIMS consensus guidelines [30], which recommended indeed to monitor every
3–4 months with brain MRI screening all NTZ-treated patients who are at high risk for devel-
oping PML.
Among the 33 symptomatic PML cases, we observed a shorter time to diagnosis in patients
who presented with cognitive symptoms than in those who presented with other symptoms.
We may speculate that cognitive and behavioural changes rather than emerging or deteriorat-
ing motor symptoms alerted clinicians to the possible PML diagnosis. As for new MRI lesions,
there is also recommendation that any new symptom or occurring beyond the first year of
treatment should be treated with suspicion [6,24,40,41]. However, fluctuations of motor func-
tion, which are frequent in patients with MS and sometimes are misinterpreted as MS relapses,
could have delayed the correct diagnosis [42]. Moreover, it has been reported that alternative
diagnoses are considered before PML in nearly two-thirds of patients, and that more than
three-quarters of PML patients suffered from diagnostic delay, irrespective of their underlying
immunosuppressive condition [43].
In our cohort, the PML diagnosis was made before the 24th months of treatment in 10
(25.6%) patients. This finding raises some concerns about the currently recommended risk
management plan that considered at higher risk for PML those patients treated with NTZ for
more than 24 months [11]. Out of 638 confirmed cases of NTZ-related PML reported at
March 2016, about 15% have been indeed diagnosed before two years of treatment, according
to manufacturer data [10]. Our data suggest that an older age at NTZ start might be a risk
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factor for developing PML before 24 infusions. Interestingly, advanced age has been reported
to be also a risk factor for PML under other MS therapies, such as fingolimod and dimethyl
fumarate [44], suggesting that age may represents an additional risk stratifier for PML in
patients treated with MS therapeutics.
The 35.9% of patients who presented with MRI enhancement at PML diagnosis is consis-
tent with recent literature that reported enhancement in 41% of cases [35]. More interestingly,
our data suggest a different clinical course between patients with and without enhancement at
PML diagnosis. In contrast with a previous observation [13], patients without contrast
enhancement experienced a worse longitudinal course than those with MRI enhancement.
This is also supported by the fact that none of the dead patients showed MRI enhancement.
Contrast-enhancement indicates an inflammatory response that often occurs in the setting of
immune restoration and may represent the first attempt to get rid of JCV [36]. Therefore, in
the absence of specific treatments against the JCV brain infection, restoration of immune sys-
tem should be considered pivotal for survival and clinical recovery and should be not impeded
by steroids, unless PML-IRIS occurs. Although we are aware that this latter hypothesis should
be considered with caution, our results deserve attention and future confirmation. Previous lit-
erature data suggested indeed that MRI enhancement of PML lesions are generally associated
with a favourable prognosis [36].
Finally, we found a 69.2% prevalence of PML-IRIS, in contrast with current literature stat-
ing that almost all patients developed PML-IRIS [17,18]. This lower PML-IRIS prevalence
seems to be not related to any demographic and clinical data, administration of PLEX, steroids,
maraviroc, mefloquine or mirtazapine. However, we cannot exclude that the widely heteroge-
neous use of steroids (different dosages, administration route and schedules) and PLEX (num-
ber of cycles) could have affected the PML-IRIS occurrence. An alternative hypothesis
encompasses a possible underestimation of patients with PML-IRIS in our cohort, since we
did not include in this subgroup those patients with early signs of PML-IRIS, as recently
described [19].
This study has several limitations and therefore its findings should be interpreted
cautiously.
Firstly, the current data are derived from an observational retrospective analysis. This
aspect, together with a relatively small sample size (PML is an uncommon adverse event),
makes difficult to overcome the exploratory nature of the study.
Secondly, as main outcome we adopted the pseudo-ordinal EDSS score, whose psychomet-
ric properties could have partially affected our findings [45]. However, EDSS was consistently
and reliably used across Italian sites to assess the disability evolution before and after the PML
diagnosis, thus allowing us to obtain a consistent and valid longitudinal measure of disability
for all patients.
Thirdly, mixed treatments were adopted to treat PML and PML-IRIS, thus missing the
chance to provide any indication about which pharmacological (e.g. mefloquine, mirtazapine,
maraviroc, PLEX, etc.) and/or non-pharmacological approach that may be potentially useful
to improve the survival rate and final outcome.
Lastly, data on anti-JCV antibodies index values are lacking, being available only since 2013
[12].
On the other hand, our study has also number of strengths, including an homogeneous
observational period length, full data availability and data harmonization which led to an uni-
form definition of PML-IRIS.
In conclusion, our analysis on Italian PML cases supports the utility of frequent MRI exam-
ination in patients treated with NTZ and confirms that early diagnosis can prevent a wide-
spread CNS involvement, leading to a more limited disease (i.e. pre-clinical presentation,
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unilobar lesion, low viral load) associated with a better outcome and higher survival rate. How-
ever, despite such encouraging observation, a relevant proportion of patients who survive
PML had substantial and permanent disability, thus requiring additional efforts to explore
potential strategies to mitigate the PML-related damage.
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